Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHI9ZJ)

• Drug Name: DL-benzylsuccinic acid Drug Info
• Synonyms: 2-Benzylsuccinic acid; 884-33-3; Benzylsuccinic acid; 2-benzylbutanedioic acid; DL-Benzylsuccinic acid; alpha-Benzylsuccinic acid; 36092-42-9; (phenylmethyl)butanedioic acid; beta-carboxybenzenebutanoic acid; D,L-Benzylsuccinic Acid; Butanedioic acid,2-(phenylmethyl)-; NSC20708; .alpha.-Benzylsuccinic acid; CHEMBL151284; CHEBI:16054; GTOFKXZQQDSVFH-UHFFFAOYSA-N; MFCD00055798; Benzenebutanoic acid, .beta.-carboxy-; 2-Benzyl-succinic acid; NSC-20708; NSC 20708; mono benzyl succinic acid; AC1L1GVE; 2-Benzylsuccinic acid #

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3858
  ChEBI ID: CHEBI:16054
  CAS Number: CAS 884-33-3
  TTD Drug ID: DMHI9ZJ

Molecule-Related Drug Atlas

Drug(s) Targeting Carboxypeptidase A1 (CPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID18078750C1b	DMO21H5	Discovery agent	N.A.	Investigative	[2]
2-Thiomethyl-3-Phenylpropanoic Acid	DMCEK6N	Discovery agent	N.A.	Investigative	[3]
SQ-14603	DMJW8NV	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Carboxypeptidase B2 (CPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-126119	DMKHM7O	Cerebrovascular ischaemia	8B1Z	Phase 1	[5]
UK-396082	DMFYKDX	Thrombosis	DB61-GB90	Phase 1	[6]
DS-1040	DMXCN37	Ischemic stroke	8B11.5Z	Phase 1	[7]
SAR-104772	DMQ9ZY0	Cerebrovascular ischaemia	8B1Z	Phase 1	[8]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[9]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[10]
PMID19954973C4	DMDYZE5	Discovery agent	N.A.	Investigative	[6]
3-mercapto-2-(piperidin-3-yl)propanoic acid	DMPJBNC	Discovery agent	N.A.	Investigative	[11]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	DMMUE05	Discovery agent	N.A.	Investigative	[12]
3-mercapto-2-(piperidin-4-yl)propanoic acid	DMYQG7A	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carboxypeptidase A1 (CPA1)	TT3LJ6G	CBPA1_HUMAN	Inhibitor	[1]
Carboxypeptidase B2 (CPB2)	TTP18AY	CBPB2_HUMAN	Inhibitor	[1]

References

• [1] A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
• [2] Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1587).
• [4] Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103.
• [5] TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
• [6] Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
• [7] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [8] Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
• [9] Clinical pipeline report, company report or official report of AstraZeneca.
• [10] Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
• [11] 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
• [12] Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.